RNA-based therapeutics are transforming medicine, but scaling production efficiently remains a challenge, particularly the cost-intensive in vitro transcription (IVT) step. Join this webinar to ...
The clinical potential of mRNA was revealed with COVID-19 vaccines, but that was just the beginning. “Today, this Nobel prize–winning technology is being leveraged for many therapeutic applications, ...
In an era where viral outbreaks can escalate into global pandemics with alarming speed, the ability to quickly develop new vaccines has become crucial. However, the speed of vaccine production is ...
Leveraging its integrated “design-synthesis-quality control” system, Creative Biolabs is overcoming bottlenecks in mRNA drug expression and in vivo stability ...
Learn from the MHRA about evolving CMC expectations, submission criteria, and initiatives for streamlining approval routes for mRNA platforms. Continuous processing: Optimizing efficiency & ...
RNA came to prominence during COVID-19 with mRNA vaccines saving millions of lives worldwide. Since then, the technology has evolved with some developers now focusing on personalized mRNA therapeutics ...
STOCKHOLM--(BUSINESS WIRE)--At the mRNA Health conference in Berlin, enginzyme and AGC Inc. presented a scalable process to produce a key mRNA vaccine and therapy ingredient, N1-methylpseudouridine-5' ...
A 3-year research program, funded by the FDA, aims to design the first continuous mRNA-manufacturing platform. Faculty at the Massachusetts Institute of Technology (MIT; MA, USA) will be leading a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results